Table 1:
Participant Characteristics
| Placebo (N=13) | Suvorexant 10 mg (N=13) |
Suvorexant 20 mg (N=12) |
|
|---|---|---|---|
| Agea (years), mean (SD) | 55.94 (6.10) | 56.95 (4.35) | 54.30 (5.66) |
| Sexb (percent, N) | F: 61.5%, 8 M: 38.5%, 5 |
F: 69.2%, 9 M: 30.8%, 4 |
F: 75%, 9 M: 25%, 3 |
| Racec (percent, N) | AA: 23.1%, 3 W: 76.9%, 10 |
AA: 30.8%, 4 W: 69.2%, 9 |
AA: 8.3%, 1 W: 91.7%, 11 |
| ApoE4+d (percent, N) | 23.1%, 3 | 30.8%, 4 | 50%, 6 |
| BMI,e mean (SD) | 27.75 (4.68) | 26.72 (3.16) | 26.96 (4.69) |
| ISI,f mean (SD) | 4.08 (4.61) | 4.62 (5.42) | 4.5 (3.61) |
| MMSE,g mean (SD) | 29.38 (0.87) | 29.23 (0.73) | 29.67 (0.49) |
| Screening actigraphy sleep efficiency (%),h mean (SD) | 72.96 (9.36) | 74.74 (7.75) | 78.82 (6.29) |
| Screening actigraphy total sleep time (min),i mean (SD) | 361.49 (59.58) | 367.62 (50.86) | 379.36 (38.55) |
SD: standard deviation; mg: milligrams; F: female; M: male; AA: African-American; W: white; ApoE4+: positive for one Apolipoprotein E4 allele; BMI: body mass index; ISI: Insomnia Severity Index; MMSE: Mini-Mental State Examination; min: minutes
No significant group differences in age. One-way ANOVA: F(2,35) 0.761, p=0.48
No significant group differences for sex. Fisher’s exact test: p=0.91
No significant group differences for race. Fisher’s exact test: p=0.48
No significant group differences for ApoE4+ status. Fisher’s exact test: p=0.39
No significant group differences in BMI. One-way ANOVA: F(2,35) 0.214, p=0.81
No significant group differences in ISI. One-way ANOVA: F(2,35) 0.048, p=0.95
No significant group differences in MMSE. One-way ANOVA: F(2,35) 1.175, p=0.32
No significant group differences in screening actigraphic sleep efficiency. One-way ANOVA: F(2,35) 1.775, p=0.18
No significant group differences in screening actigraphic total sleep time. One-way ANOVA: F(2,35) 0.397, p=0.68